Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Feb 2011

Spraggs Colin F, Budde Laura R, Briley Linda P, Bing Nan, Cox Charles J, King Karen S, Whittaker John C, Mooser Vincent E, Preston Alaknanda J, Stein Steven H, Cardon Lon R

Abstract excerpt

PURPOSE: Hepatobiliary adverse events (AEs) have been observed in a small proportion of patients with metastatic breast cancer (MBC) treated with lapatinib. This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs. PATIENTS AND METHODS: A two-stage pharmacogenetic investigation of ALT elevation was conducted in lapatinib-treated patients with MBC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to HLA-DQ alpha-Chains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ Antigens

Share to Lapatinib

Share to Liver Diseases

Share to Liver Function Tests

Share to Quinazolines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 21245432
DOI: 10.1200/JCO.2010.31.3197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.PMID 21245432Read ↗

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.Semantic proximity Read ↗

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.Semantic proximity Read ↗

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Semantic proximity Read ↗

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.Semantic proximity Read ↗

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Semantic proximity Read ↗

Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.Semantic proximity Read ↗

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury.Semantic proximity Read ↗

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.Semantic proximity Read ↗

Relationship between HLA-DRB1 gene polymorphism and breast cancer: A protocol for systematic review and meta-analysis.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.